Enbrel Decreases Inflammatory Markers in Metabolic Syndrome - CME Teaching Brief - MedPage Today: "BOSTON, April 25 — Blocking a key protein with Enbrel (etanercept) improves several inflammatory markers in patients with metabolic syndrome, according to researchers here.
In a small randomized trial, patients treated with the agent had lower levels of C-reactive protein and higher levels of adiponectin—indications of a decrease in the inflammation thought to be a key link between the syndrome and cardiovascular risk, said Steven Grinspoon, M.D., of Massachusetts General Hospital here.
Results of the study, published in the April 25 issue of Archives of Internal Medicine, amount to 'proof of principle,' Dr. Grinspoon said in a statement, and 'sheds light on the physiology of inflammation and its relation to cardiac risk in obese patients.'"
No comments:
Post a Comment